Authorization

China is funding the future of American biotech

Silicon Valley is in the midst of a health craze, and it is being driven by Eastern medicine.
Its been a record year for US medical investing, but investors in Beijing and Shanghai are now increasingly leading the largest deals for US life science and biotech companies.In fact, Chinese venture firms have invested more this year into life science and biotech in the US than they have back home,providing financing for over 300 US-based companies, per Pitchbook.Thats the story at Viela Bio, a Maryland-based company exploring treatments for inflammation and autoimmune diseases, which raised a $250 million Series A led by three Chinese firms.
Chinese capitals newfound appetite also flows into the mainland.Business is booming for Chinese medical startups, who are also seeing the strongest year of venture investment ever, with over one hundred companies receiving $4 billion in investment.
As Chinese investors continue to shift their strategies towards life science and biotech, China is emphatically positioning itself to be a leader in medical investing with a growing influence on theworlds future major health institutions.

Chinese VCs seek healthy returns


We like to talk about things we can interact with or be entertained by.And so as nine-figure checks flow in and out of China with stunning regularity, wefixate on the internet giants, the gaming leaders or the latest media platform backed by Tencent or Alibaba.
However, if we follow the money, its clear that the top venture firms in China have actually been turning their focus towards the countrys deficient health system.
A clear leader in Chinas strategy shift has been Sequoia Capital China, one of the countrys most heralded venture firms tied to multiple billion-dollar IPOs just this year.
Historically, Sequoia didnt have much interest in the medical sector. Health was one of thefirms smallest investment categories, and it participated in only three health-related deals from 2015-16, making up just 4% ofits total investing activity.
Recently, however, life sciences have piqued Sequoias fascination, confirms a spokesperson with the firm. Sequoia dove into six health-related deals in 2017 and has already participated in 14 in 2018 so far. The firm now sits among the most active health investors in China and the medical sector has become its second biggest investment area, with life science and biotech companies accounting for nearly 30% of its investing activity in recent years.
China is funding the future of American biotech
Health-related investment data for 2015-18 compiled from Pitchbook, Crunchbase, and SEC Edgar
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«     2019    »
1234567
891011121314
15161718192021
22232425262728
293031